Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year ...

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets.

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

Pfizer's stock was charging 4.5% higher in recent trading, and was sharing the top spot on the S&P 500's gainers list with Fox Corp., after the drug maker provided profit and revenue guidance.

Pfizer Inc. (NYSE:PFE – Free Report) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Pfizer in a report issued on Wednesday, December 18th. Leerink Partnrs ...

Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it ...